Home » Topics » Regulatory

Regulatory
RSS

Novartis files NDA for extended-release formulation of fluvastatin

Dec. 16, 1999

NIH-sponsored study fails to confirm efficacy of secretin in autism

Dec. 14, 1999

Mallinckrodt's MRI contrast agent approved for marketing in U.S.

Dec. 13, 1999

Dusa receives first approval of Levulan PDT for treatment of actinic keratoses

Dec. 10, 1999

Zoloft receives FDA approval for posttraumatic stress disorder

Dec. 10, 1999

Novartis reports setbacks and advances in the development of new chelating agents

Dec. 8, 1999

FDA advisory panel will review MS indication for Novantrone in early 2000

Dec. 8, 1999

Nasonex Nasal Spray approved for new pediatric indication in U.S.

Dec. 3, 1999

FDA approves new epilepsy treatment

Dec. 2, 1999

V1A/AT1 receptor antagonist combinations for cardiovascular disorders

Dec. 2, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...